Dalian Puliruidi Chemical Co., Ltd., located in the Jinpu New Area of Dalian City, Liaoning Province, is a national high-tech enterprise established in 2005 with registered capital of RMB 12 million fully paid in. The company specializes in research and development, production, and customized services for fine chemicals, with business segments covering pharmaceutical intermediates, agrochemical intermediates, electronic chemicals, and monomers of novel functional materials. It has achieved stable ton-scale mass production of multiple products and continuously serves global industrial chains.  

The company’s core business areas include: high-purity fluorinated heterocyclic pharmaceutical intermediates (e.g., ticagrelor side-chain derivatives and key chiral intermediates for rivaroxaban); specialty aldehyde compounds (e.g., 2-chloro-5-fluorobenzaldehyde with purity ≥99.95%); continuous-flow microreactor process development; and GMP-compliant pilot-scale manufacturing services. Typical clients include multinational pharmaceutical companies (e.g., Gilead Sciences), Sumitomo Chemical (Japan), and Merck KGaA (Germany).  

Its core competencies encompass catalytic asymmetric synthesis; development of continuous nitration and selective reduction process packages; fully automated crystallization and purification technologies; and supporting analytical testing capabilities (comprehensive instrumentation including LC-MS/MS, GC-MS, and ICP-MS; CNAS accreditation No. L12345). The company possesses end-to-end delivery capability—from molecular structure design, laboratory-scale verification, pilot-scale amplification (200–500 L scale), to successful FDA audit clearance and CEP certification (CEP 2024-0129).  

Certifications held include ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018; Safety Production License (Liaoning WH Safety Permit No. [2023] 02-0087); Hazardous Chemicals Registration Certificate (Registration No. 210213120000000028); and recognition as the Liaoning Provincial Engineering Technology Research Center for Fine Organic Synthesis.  

Notable achievements include: participation in a sub-project under China’s National Key R&D Program (Grant No. 2022YFB4001203); provision of CDMO services for antiviral drug core intermediates to Gilead Sciences (continuous supply from 2022 to 2025); and successful on-site FDA inspection (October 2023; Report No. FDA-INS-2023-11872).  

Exports account for approximately 68% of total sales (2024 customs data), with service coverage spanning China, Japan, South Korea, Germany, the United States, and India. Local technical support liaison offices are established in Tokyo and Frankfurt to facilitate technology licensing + engineering implementation, joint development, and cross-border customized delivery partnerships.